`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`77486429
`
`Omega Alpha Pharmaceuticals Inc.
`OMEGA ALPHA
`
`Eugenia S. Hansen
`Hemingway & Hansen, LLP
`Suite 48001700 Pacific Avenue
`Dallas, TX 75201
`UNITED STATES
`
`ghansen@hh-ip|aw.com
`
`Appeal Brief
`
`01/17/2012
`
`FinalBriefwith Signature.pdf ( 23 pages )(344685 bytes)
`TAB A Cover.pdf ( 1 page )(19977 bytes)
`Bayer Case for Tab A.pdf ( 7 pages )(243555 bytes )
`
`Eugenia S. Hansen
`
`ghansen@hh—ip|aw.com,adavis@hh—ip|aw.com
`/es hansenl
`
`Trademark Trial and Appeal Board Electronic Filing System. http://estta.uspto.gov
`ESTTA451653
`ESTTA Tracking number:
`01/17/2012
`
`Filing date:
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`77486429
`Omega Alpha Pharmaceuticals Inc.
`OMEGA ALPHA
`Eugenia S. Hansen
`Hemingway & Hansen, LLP
`Suite 48001700 Pacific Avenue
`Dallas, TX 75201
`UNITED STATES
`ghansen@hh-iplaw.com
`Appeal Brief
`FinalBriefwith Signature.pdf ( 23 pages )(344685 bytes )
`TAB A Cover.pdf ( 1 page )(19977 bytes )
`Bayer Case for Tab A.pdf ( 7 pages )(243555 bytes )
`Eugenia S. Hansen
`ghansen@hh-iplaw.com,adavis@hh-iplaw.com
`/es hansen/
`01/17/2012
`
`Proceeding
`Applicant
`Applied for Mark
`Correspondence
`Address
`
`Submission
`Attachments
`
`Filer's Name
`Filer's e-mail
`Signature
`Date
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Applicant: Omega Alpha Pharmaceuticals Inc
`
`Trademark: OMEGA ALPHA (and design)
`
`Serial No.: 77486429
`
`
`
`Filing Date: May 29, 2008
`
`
`
`
`
`
`
`
`
`
`
`
`
`)
`
`) BEFORE THE
`
`) TRADEMARK TRIAL
`
`
`
`) AND
`
`Examining Attorney: Darryl M. Spruill
`
`Address: Law Office 112
`
`
`
`
`
`
`
`
`
`
`) APPEAL BOARD
`
`) ON APPEAL
`
`APPELLANT’S APPEAL BRIEF
`
`
`
`1
`
`
`
`
`
`
`
`
`
`TABLE OF CONTENTS
`
`FACTS ............................................................................................................................ 4
`
`ARGUMENT .................................................................................................................... 6
`
`A. Legal Standard ...................................................................................................... 6
`
`B. The Examining Attorney Erred and Should Be Reversed ...................................... 6
`
`1. The Examining Attorney Erred by Assuming “Omega” is a Material or
`Substance and Rejecting Appellant’s Evidence to the Contrary ............................... 6
`
`2. The Examiner’s Own Record Evidence Refutes the Assertion that Consumers
`Would Perceive “Omegas” as Health-Promoting Substances ................................ 13
`
`3. The Weight of the Evidence Indicates That OMEGA ALPHA draws meaning
`from the Greek Alphabet and Literature Connotations Employing Both of The
`Letters ..................................................................................................................... 15
`
`4. The Examining Attorney Failed to Consider Appellant’s Mark As a Whole ...... 15
`
`5. The Design Elements of OMEGA ALPHA (and design) Cannot Be Ignored .... 17
`
`6. Prior Registrations by Appellant and Third Parties of Marks Containing “Alpha”
`and “Omega” are Persuasive of Lack of Descriptiveness or Misdiscriptiveness ..... 20
`
`a. Appellant’s Prior Registrations…………………………………………………….19
`
`1) OMEGA ALPHA PHARMACEUTICALS (U.S. Registration 3,111,385)
`
`2) Canadian Registration of OMEGA ALPHA (and design)
`
`b. Third Party Registrations
`
`CONCLUSION .............................................................................................................. 21
`
`
`
`
`
`2
`
`
`
`
`
`
`
`TABLE OF AUTHORITIES
`
`Cases
`
`A.F. Gallun v.Aristocrat Products, 135 USPQ 459, 460 (TTAB 1962) ..................... 15, 16
`
`Bayer Aktiengesellschaft v. Mouratidis, 2010 TTAB LEXIS 218 (TTAB May 21, 2010).
` ............................................................................................................................. 11, 12
`
`In re Alp of South Beach Inc., 79 USPQ 2d 1009, 2006) ............................ 10, 10n, 11,14
`
`In re Atavio Inc, 25 USPQ2d 1361 (TTAB 1992). .......................................................... 22
`
`In re Budge Mfg. Co., 857 F.2d 773, 8 USPQ 2d 1259 (Fed. Cir. 1988). .......... 10, 11, 16
`
`In re Colonial Stores Inc., 394 F. 2d 549, 157 USPQ 382 (CCPA 1968) ................. 18, 19
`
`In re Phillips-Van Heusen Corp., 63 USPQ2d 1047 (TTAB 2002). ................................ 12
`
`In re Save Venice N.Y., Inc., 259 F.3d 1346, 59 USPQ 2d 1778 (Fed. Cir. 2001). ......... 6
`
`In re Shutts, 217 USPQ 363 (TTAB 1983) .................................................................... 19
`
`In re Standard Elektrik Lorenz Aktiengesellschaft, 371 F.2d 870, 152 USPQ 563 (CCPA
`1967) ............................................................................................................................ 6
`
`In re Woolrich Woolen Mills, Inc., 13 USPQ 2d 1235 (TTAB 1989) ......................... 16, 17
`
`Tektronix, Inc. v. Daktronics, Inc., 534 F.2d 915, 916, 189 USPQ 693 (CCPA 1976) ... 21
`
`Statutes
`
`15 U.S.C. §1052(a) ..................................................................................................... 4, 6
`
`Other Authorities
`
`T.M.E.P. § 1209.03(d) ................................................................................................... 18
`
`
`
`3
`
`
`
`
`
`INTRODUCTION
`
`Appellant has appealed the trademark Examining Attorney’s final refusal dated
`
`May 22, 2011. The final refusal of Appellant’s application to register the trademark
`
`OMEGA ALPHA (and design) under 15 U.S.C. §1052(a)is based on the grounds that
`
`the mark consisted of or included deceptive matter in relation to the identified goods.
`
`FACTS
`
`Applicant/Appellant (hereinafter “Appellant”) filed an application to register the
`
`mark OMEGA ALPHA (and design), in connection with goods classified in International
`
`Class 005 (IC 005) on May 8, 2008. After review by the United States Patent and
`
`Trademark Office (“USPTO”) Examining Attorney, the only grounds for rejection were
`
`directed to the manner of identification of the goods, the claim of ownership to U.S.
`
`Registration 3,111,385, OMEGA ALPHA PHARMACEUTICALS, and to clarification of
`
`the filing basis. See Official Action of 10/15/2008. From April 15, 2009 through July 7,
`
`2010, these three issues were the only issues raised.
`
`On July 7, 2010, another official action was mailed, stating that after further
`
`consideration and review, an additional rejection based on 15 U.S.C. § 1052(a) had
`
`been added. See Official Action of 7/7/2010. The Examining Attorney included 58
`
`attachments which pertained to searches conducted on the term “omega” and variations
`
`thereof. The full office action contains 87 pages.1 Appellant responded to this Official
`
`Action on January 6, 2011. With this response, Appellant submitted Exhibit 1 (Article
`
`supporting the meaning of OMEGA ALPHA per the Greek letters) pp. 6-10; Exhibit 2
`
`
`1 Each page referenced herein will use the page number of the 87 pages.
`
`
`
`4
`
`
`
`(Third party registrations utilizing “alpha” and “omega”) pp. 11-20; Exhibit 3 (Copy of
`
`Appellant’s prior registration of OMEGA ALPHA PHARMACEUTICALS) pp. 21-22 and
`
`Exhibit 4 Third party registration of “Everything from Alpha to Omega” in connection with
`
`dietary supplements and evidence of use of the mark OMEGA ALPHA by the Appellant
`
`on goods) pp. 23-247. Appellant argued against the deceptiveness rejection and
`
`offered arguments contra to the Examining Attorney’s position. See Response to
`
`Official Action of 7/7/2010 (filed 1/6/2011).
`
`However, a new Examining Attorney finally rejected the application for
`
`registration, deeming Appellant’s arguments “unpersuasive.” See Official Action of
`
`5/22/2011. Despite Appellant’s submission of Exhibit 1(described supra) with its
`
`response, the Examining Attorney stated that Appellant had presented no evidence
`
`demonstrating that consumers would perceive the meaning of OMEGA ALPHA as
`
`meaning “from the end to the beginning.” See Official Action of 5/22/2011 at 16.
`
`Further, additional references were cited by the new Examining Attorney to internet
`
`mentions of omega-3 fatty acids in various articles and advertisements. See id. at 16-
`
`17. The Examining Attorney concluded that the use of “OMEGA” in Appellant’s mark
`
`misdescribed the goods since all of the goods “do not feature omegas.” See id. at 17.
`
`The Examining Attorney concluded that the evidence of record, “[c]ontrary to Appellant’s
`
`position…” demonstrates that consumers would specifically purchase supplements on
`
`the premise that the term OMEGA would denote that the goods encompass Omega
`
`fatty acids based on the essential health and/or nutritional value that omegas provide for
`
`both humans and pets.”
`
`
`
`5
`
`
`
`Because the Examining Attorney was satisfied with the Appellant’s identification
`
`of goods, the sole issue remaining is the final rejection under 15 U.S.C. §1052(a).
`
`Appellants filed a Notice of Appeal on November 18, 2011.
`
`A. Legal Standard
`
`ARGUMENT
`
`The United States Patent and Trademark Office (“USPTO”) has the burden of
`
`proving that a trademark falls within a prohibition of Sec. 1052. See In re Standard
`
`Elektrik Lorenz Aktiengesellschaft, 371 F.2d 870, 873, 152 USPQ 563, 566 (CCPA
`
`1967). On appeal, the USPTO’s finding of fact is reviewed for substantial evidence.
`
`See In re Save Venice N.Y., Inc., 259 F.3d 1346, 1351, 59 USPQ 2d 1778 (Fed. Cir.
`
`2001). If the USPTO’s Examining Attorney puts forward a prima facie case, then the
`
`Appellant’s rebuttal evidence is considered to determine if it sufficiently rebutted the
`
`evidence of the USPTO.
`
`B. The Examining Attorney Erred and Should Be Reversed
`
`1. The Examining Attorney Erred by Assuming “Omega” is a Material or
`Substance and Rejecting Appellant’s Evidence to the Contrary
`
`The registration of OMEGA ALPHA (and design) was finally refused on the
`
`grounds that “the applied-for mark consisted of or included deceptive matter in relation
`
`to the identified goods.” Appellant respectfully submits that the Examining Attorney
`
`erred in refusing registration on these grounds. Because the final refusal dated May 22,
`
`2011 (Official Action of 5/22/2011) augments and adopts the previous Official Action
`
`dated July 7, 2010 (Official Action of 7/7/2010), both will be discussed herein.
`
`
`
`6
`
`
`
`The Examining Attorney has rested the final refusal on a conclusion that “all but
`
`three of the above listed goods do not feature omegas,” and failing to give weight to
`
`Appellant’s prior arguments that “omega” does not signify an ingredient in any one of its
`
`listed goods, but instead is an arbitrary designation when considered in connection with
`
`the listed goods and when the mark as a whole, OMEGA ALPHA (and design), is
`
`considered. See Response to Official Action of 7/7/2010 (filed 1/6/2011) at 3 (wherein
`
`Appellant argued that Appellant’s mark does not contain the terms “omega-3,” “omega-
`
`6,” or “fatty acids” and thus will be perceived as Greek letters and not as a message to
`
`consumers about omega-3 fatty acids; and that the 24th letter of the Greek alphabet,
`
`“omega” and the 1st letter of the Greek alphabet, “alpha” when placed together to create
`
`the new designation “OMEGA ALPHA (and design)” does not describe (or “misdescribe”
`
`as contended by the Examining Attorney) any ingredients whatsoever that may be
`
`present in the goods). See id. at 3.
`
`The Examining Attorney failed to set forth a prima facie case, because all of the
`
`evidence set forth concerns omega-3 fatty acids, omega-6 fatty acids and/or other types
`
`of fatty acids. The Examining Attorney erred, and therefore did not establish a prima
`
`facie case, because the Examining Attorney equated the Greek letter “omega,” standing
`
`alone, with “omega-[numeral] fatty acids.” This is error on the part of the Examining
`
`Attorney, because there is no chemical or biological ingredient in existence which is
`
`called an “omega” or “omegas” and thus the Examining Attorney’s evidence does not
`
`even pertain to Appellant’s mark. Appellant argued this previously. See Response to
`
`Official Action of 7/7/2010 (filed 1/6/2011) at 3 (Failing to consider the mark in its
`
`entirety, the Examining Attorney contends that the term “OMEGA” in Appellant’s
`
`
`
`7
`
`
`
`OMEGA ALPHA (and design) mark will be viewed as having a nutritional meaning).
`
`Even though Appellant previously pointed out that the evidence provided by the
`
`Examining Attorney referred only to “omega-3” fatty acids, “omega-6” fatty acids or
`
`“omega-9 fatty acids” and that “OMEGA” alone had no nutritional meaning, the rejection
`
`was made final.
`
`Expanding upon Appellant’s previous argument, Appellant points again to
`
`evidence placed in the record by the Examining Attorney. Although Appellant contends
`
`that its mark has a meaning “from the end to the beginning” from the Greek letters
`
`“omega” and “alpha,” (see Response to Official Action of 7/7/2010 (filed 1/6/2011) at
`
`Exhibit 1) even considering the Examining Attorney’s venture into the
`
`chemical/nutritional sciences with the citations to dictionaries and articles concerning
`
`fatty acid chemistry and chemical nomenclature, Appellant contends that the Examining
`
`Attorney has misused the chemical terminology so as to render it meaningless in the
`
`context of considering the registrability of Appellant’s trademark. In chemistry, the word
`
`“omega” is used to pronounce the Greek letter “ώ,” used in chemical nomenclature to
`
`indicate a location of a carbon atom with respect to the molecule as a whole. For
`
`example in fatty acids, which are straight-chain hydrocarbons (molecules having carbon
`
`and hydrogen) having an acid carboxyl (COOH) group at one end, the Greek letters of
`
`the alphabet are used to designate which carbon of the molecule is being discussed.
`
`The carbon next to the carboxyl group is known as the “α” carbon, the next carbon, the
`
`“β” carbon, and so forth. Since fatty acids can be of different lengths, the last carbon
`
`position on the fatty acid is labeled as the "ω" [aka “omega”] carbon, from the last letter
`
`in the Greek alphabet. See, e.g., Official Action Of 7/7/2010 at 50 (the Examining
`
`
`
`8
`
`
`
`Attorney’s evidence consisting of the article, William E. Butler, “Omega-3 Fatty Acids -
`
`Science, Efficacy, and Clinical Use in Cardiology”). With respect to fatty acids, some
`
`are “unsaturated” fatty acids and some are “saturated” fatty acids. See id. at 49 (Butler
`
`article cited by Examining Attorney stating that omega-3 and omega-6 fatty acids are
`
`polyunsaturated fatty acids (PUFA) and differ from other fatty acids by the structure of
`
`their carbon chains). As stated in Butler, PUFA have double bonds between carbons.
`
`See id. To indicate the position of the double bonds in relation to the “ώ” (omega) or
`
`last carbon of the fatty acid, a numeral must be placed after the “omega” designation.
`
`Thus, “omega-3” fatty acids are those that have a double bond between the third carbon
`
`and fourth carbon, counting from the omega position. See id. at 50. The term “omega-
`
`6 fatty acids” signifies a fatty acid with a double bond between the sixth and seventh
`
`carbon, counting from the omega position. Thus, the Examining Attorney’s conclusion
`
`that few of Appellant’s goods contain “omegas” is incorrect. In fact, none of Appellant’s
`
`goods contain “omegas” nor do any other compositions in the world contain “omegas.”
`
`“Omega” (ώ) is simply a Greek letter signifying a position of a carbon, and is not a
`
`substance.
`
`The fact that the Examining Attorney’s own evidence refers to “omega-3 fatty
`
`acids” indicates that the bolded portion of the quoted term is necessary for the term to
`
`make any correct sense as a name of a substance. In fact, without the use of the “-3”
`
`the term is nonsensical as a reference to a substance. Again citing the Examining
`
`Attorney’s own evidence in the record, the definition for the term “omega” refers (as a
`
`noun) to the last letter of the Greek alphabet and (as an adjective) to “of or
`
`characterizing a chemical group or position at the end of a molecular chain…” See
`
`
`
`9
`
`
`
`Official Action of 7/7/2010 at 61(excerpt from The Free Dictionary). There are many
`
`possible positions for double bonds in an unsaturated molecule and the number is
`
`necessary to provide an indication of the properties of the fatty acid. See id. at 50
`
`(Butler article).
`
`The case before this Board is not similar, therefore, to the case cited by the
`
`Examining Attorney, namely, In re Budge Mfg. Co., 857 F. 2d 773, 8 USPQ 2d 1259
`
`(Fed. Cir. 1988). In the Budge case, the Federal Circuit considered LOVEE LAMB in
`
`connection with automotive seat covers. The Appellant for registration admitted that the
`
`covers were not made of lambskin or sheepskin, but of synthetic material. Thus, the
`
`court concluded that “LAMB” was misdescriptive of the goods. The Budge case is
`
`inapplicable to the instant situation because, as pointed out above, there is no such
`
`thing as an “omega” chemical or biological substance. Thus, no analysis can even be
`
`conducted as to whether Appellant’s goods contain “omegas” or not. Thus, the three
`
`pronged test used in Budge fails at the first prong for reasons of inability to apply it to
`
`Applicant’s goods.
`
`The Examining Attorney further cited In re Alp of S. Beach Inc., 79 w 1009 [sic.]
`
`(TTAB 2006).2 Alp is also inapplicable to the present situation. In Alp, the Appellant
`
`sought to register CAFETERIA for restaurant services that did not include cafeteria-style
`
`service. In applying the three-pronged test for determining whether a mark is deceptive
`
`under Section 2(a), this Board considered:
`
`
`2 Appellant believes that the Examining Attorney intended to cite In re Alp of South Beach Inc.,
`79 USPQ 2d 1009, (TTAB 2006) and will proceed on that basis.
`
`
`
`10
`
`
`
`(1) Is the term misdescriptive of the character, quality, function, composition or use
`
`of the goods (or services)?
`
`(2) If so, are prospective purchasers likely to believe that the misdescription actually
`
`describes the goods (or services)?
`
`(3) If so, is the misdescription likely to affect the decision to purchase?
`
`See In re Alp of South Beach Inc., 79 USPQ 2d 1009 (TTAB 2006)
`
`Alp, like Budge, is distinguishable from the case at bar. Since “ώ” (omega) is an
`
`indication of a position of a carbon atom in a molecule, not a substance, prong (1) of the
`
`test cannot even be analyzed with respect to Appellant’s goods. The necessity for there
`
`to be a term in the proposed mark that can be analyzed in prong (1) of the test was
`
`explained by this Board in Bayer Aktiengesellschaft v. Mouratidis, slip. op., 2010 TTAB
`
`LEXIS 218, 7-8 (TTAB, May 21, 2010). (Attached at TAB A) There it was stated:
`
`“As a starting point for analysis, we observe that for a term to misdescribe goods, the
`
`term must be merely descriptive of a significant aspect of the goods which the goods
`
`could plausibly possess but in fact do not.”
`
`The “starting point for analysis” referenced in Bayer cannot be determined in the
`
`instant case. “Omega” cannot be merely descriptive of any significant aspect of
`
`Appellant’s goods which the goods could plausibly possess, but in fact, do not. No
`
`product could plausibly possess an “omega.” Unlike the cases cited by the Examining
`
`Attorney or which consider the issue, when one looks up “omega” in the dictionary, one
`
`obtains the definition put into evidence by Appellant and the Examining Attorney (e.g.,
`
`“omega” is the last letter of the Greek alphabet). Appellant’s goods cannot be so
`
`
`
`11
`
`
`
`analyzed because there is no such material as “omega” nor any adjective applicable to
`
`an ingredient as an “omega” type ingredient.
`
`While Bayer’s Board could determine that “Appellant's dietary supplements do
`
`not contain acetylsalicylic acid otherwise known as aspirin,” this Board cannot
`
`determine whether or not Appellant’s goods contain “omega" as defined in the
`
`dictionary.
`
`Further, the case of In re Phillips-Van Heusen Corp., 63 USPQ 2d 1047, 1051
`
`(TTAB 2002), cited by the TTAB in Bayer and by the Examining Attorney in the instant
`
`case, supports Appellant’s position. In Phillips, the Board affirmed the refusal to register
`
`SUPER SILK in connection with clothing that did not contain silk. However, in making
`
`its determination in Phillips, the Board relied upon dictionary definitions of “super” and
`
`“silk” and approved the examining attorney’s logic that “super” modified “silk” which was
`
`a noun. See id. In the present case, the dictionary definitions of “omega” put into the
`
`record by both Appellant and the Examining Attorney define “omega” as the last letter of
`
`the Greek alphabet. Following the analysis in Phillips compels a conclusion that
`
`“omega” is a Greek letter, not a chemical or nutritional ingredient as is contended by the
`
`Examining Attorney. The Examining Attorney is simply not supported by the record
`
`evidence.3
`
`Further, as is detailed below, Appellant’s mark is OMEGA ALPHA (and design)
`
`and the evidence of record supports that when an observer views “OMEGA” in
`
`3 The primary definitions of the words, “omega” and “alpha” respectively, are definitions of each as a
`Greek letter when they serve as nouns. Thus, when one says “OMEGA ALPHA” one is pronouncing two
`nouns in succession. This reinforces that the consumer will ascribe the Greek letter definition to them.
`Consider the hypothetical mark “ABC.” It would be nonsensical to analyze if “A” alone is a potential
`ingredient of the goods.
`
`
`
`12
`
`
`
`conjunction with “ALPHA”, one would perceive Greek letters, as those two letters used
`
`together connote “from the end to the beginning.” See Response to Official Action of
`
`7/7/2010 (filed 1/6/2011) at Exhibit 1.
`
`
`
`2. The Examiner’s Own Record Evidence Refutes the Assertion that
`Consumers Would Perceive “Omegas” as Health-Promoting
`Substances
`
`The Examining Attorney’s own evidence, the Butler article, differentiates between
`
`the properties of “omega-3 fatty acids” and “omega-6 fatty acids,” stating that intake of a
`
`disproportionate ratio of “omega-6 fatty acids” to “omega-3 fatty acids” could be
`
`implicated in inflammatory disease. See Official Action Of 7/7/2010 at 50 (the
`
`Examining Attorney’s evidence consisting of the article, William E. Butler, “Omega-3
`
`Fatty Acids -Science, Efficacy, and Clinical Use in Cardiology”). The Examining
`
`Attorney’s evidence also refers to “omega-9 fatty acids.” See id. at 82. These are
`
`commonly found in animal fats such as bacon fat and lard. Although also bearing the
`
`“omega” descriptor (to describe the position of the double bond relative to the last
`
`carbon atom in the fatty acid), “omega-9” fatty acids are not “essential” fatty acids and
`
`are made by the animal’s body. They have been implicated in “possible negative
`
`health effects.” See Official Action of 7/7/2010 at 82 (emphasis added).
`
`Thus, the Examining Attorney’s conclusion that consumers would “specifically
`
`purchase supplements on the premise that the term OMEGA would denote that the
`
`goods encompass Omega fatty acids based on the “essential health” and/or
`
`“nutritional value” (Official Action of 5/22/2011 at 17 (emphasis added)) that omegas
`
`
`
`13
`
`
`
`provide for both humans and pets” is simply a non-sequitur. Since there is no such
`
`chemical substance as an “omega” (because this refers to a position of a carbon atom
`
`in a molecule, not a substance4) and even if the correct entities (e.g., omega-[numeral]
`
`fatty acids) are considered, the Examining Attorney’s own evidence of record
`
`establishes that not all “omega – [numeral] fatty acids” are healthy or essential and thus
`
`consumers would not likely assume that Appellant’s products encompass them.
`
`The evidence in the record, as a whole, does not support the Examining
`
`Attorney’s premise. Evidence that omega-9 fatty acids are not essential and potentially
`
`harmful and that intake of omega-6 fatty acids, though essential, should not greatly
`
`exceed the intake of omega-3 fatty acids is also a part of this record and cannot be
`
`ignored.
`
`Thus, even if one ignores the fact that there is no such ingredient as an “omega,”
`
`the second prong of the test – whether prospective purchasers are likely to believe that
`
`the misdescription actually describes the goods or services - cannot be satisfied. See
`
`Alp, supra, page 11. There is no evidence that prospective purchasers would believe
`
`that “omega” would be contained in products bearing the mark OMEGA ALPHA (and
`
`design). Given the contradictory evidence, that not all “omega – [numeral] fatty acids”
`
`should be taken in, such a conclusion could never be reached.
`
`
`4 “Omega” and “alpha” are both indicators of particular carbon atoms in fatty acid molecules. If
`it is nonsensical to consider whether Appellant’s goods contain or do not contain “alphas” then it
`is equally nonsensical to consider whether Appellant’s goods contain or do not contain
`“omegas.”
`
`
`
`14
`
`
`
`There is also no evidence that if the first two prongs were somehow satisfied that
`
`this would affect the purchasing decision. The three-pronged test cannot be met at any
`
`level.
`
`3. The Weight of the Evidence Indicates That OMEGA ALPHA draws
`meaning from the Greek Alphabet and Literature Connotations
`Employing Both of The Letters
`
`Appellant’s evidence in Exhibit 1 to its Response to Official Action of 7/7/2010
`
`fully rebutted the case of the Examining Attorney. Appellant’s evidence is that (1)
`
`“Omega Alpha” is a combination of the last and first letters of the Greek alphabet, and
`
`(2) that this term would mean “from the ending to the beginning.” Exhibit 1 details the
`
`biblical and historical meaning of “alpha” and “omega” when used together.
`
`In fact, the Examining Attorney also submitted evidence into the record which
`
`agrees with Appellant’s premise that the primary meaning of “omega,” when used as a
`
`noun, is as the last letter of the Greek alphabet. See Official Action of 7/7/2010 at 61.
`
`Thus, there is substantial evidence in the record supporting Appellant’s position
`
`that consumers would perceive Appellant’s mark OMEGA ALPHA (and design) as
`
`referring to the Greek letters “omega” and “alpha”.
`
`4. The Examining Attorney Failed to Consider Appellant’s Mark As a
`Whole
`
`Appellant’s mark is OMEGA ALPHA (and design), not “omega.” Appellant
`
`contends that the Examining Attorney has impermissibly dissected the mark to conclude
`
`that it is misdescriptive. In determining whether a mark is deceptive, the mark must be
`
`considered in its entirety. See A.F. Gallun v. Aristocrat Products, 135 USPQ 459, 460
`
`
`
`15
`
`
`
`(TTAB 1962) (COPY CALF, not CALF, was the mark sought to be registered and the
`
`commercial impression of a mark is necessarily derived from it as a whole; therefore the
`
`unitary phrase must be considered). Though a different approach was taken in Budge,
`
`supra (where the Court considered the LAMB portion of LOVEE LAMB), whichever
`
`approach is used does not result in satisfaction of prong (1) of the test when one
`
`considers Appellant’s mark OMEGA ALPHA (and design). Unlike in Budge and Gallun,
`
`there is no single word in Appellant’s mark that standing alone is a material or ingredient
`
`from which something can be fabricated or made.
`
`Appellant has located no cases precisely on point to the instant case (in which
`
`the Examining Attorney premised a misdescriptiveness rejection on a portion of a mark
`
`(“OMEGA”) that the Examining Attorney’s own record evidence makes clear is not in
`
`fact a material from which anything can be made. However, of the cases available for
`
`citation, Appellant’s mark is more similar to the mark considered in In re Woolrich
`
`Woolen Mills, Inc., 13 USPQ 2d 1235 (TTAB 1989) than to the marks in the cases relied
`
`on by the Examining Attorney. In Woolrich, the Board reversed the refusal to register
`
`WOOLRICH in connection with clothing which might not be made of wool. The
`
`Examining Attorney had taken the position that a consumer would believe that the
`
`clothing was rich in wool, and that therefore, the mark was misdescriptive. The Board
`
`considered WOOLRICH as a whole, not just the “wool” portion, and noted “a number of
`
`well-known people have had surnames beginning with "wool" or ending with "rich", e.g.,
`
`Frank Woolworth, Alexander Woollcott, and Samuel Goodrich and that it was
`
`permissible for the Board to consider these factors in determining consumer perception.
`
`
`
`16
`
`
`
`The WOOLRICH Appellant also had some other marks which had long been in use in
`
`connection with wool and non-wool clothing.
`
`In addition, Appellant’s prior registration for OMEGA ALPHA
`
`PHARMACEUTICALS (U.S. Reg. 3,111,385), and evidence of use of that mark and the
`
`mark OMEGA ALPHA (and design) is used in connection with a wide variety of
`
`supplement products (Response to the Office Action of 7/7/2010 at Exhibit 4) are similar
`
`factors to those found persuasive to the Board in Woolrich.
`
`When one reviews the manner of use by Appellant of the mark at issue, it is even
`
`clearer that the mark is generally utilized as a house mark in conjunction with another
`
`mark or a product name. The use by Appellant which was put into evidence shows that
`
`Appellant details the nature of the goods and the proposed application to human, pet, or
`
`equine health. Thus, the manner of use further supports that the mark would not be
`
`perceived by the consumer as deceptively misdescriptive.
`
`5. The Design Elements of OMEGA ALPHA (and design) Cannot Be
`Ignored
`
`The mark at issue in this appeal is OMEGA ALPHA (and design). However, the
`
`design elements of the mark have been improperly dissected from the analysis. Only
`
`one word used in the composite mark, namely OMEGA, has been analyzed and used to
`
`reject Appellant’s application for registration.
`
`
`
`17
`
`
`
`
`
`
`
`
`
`
`
`of the capi
`
`tal Greek
`
`
`
`wing USSN 774886441 Draw
`
`
`
`
`
`
`
`
`
`AAppellant’s mmark includdes a graphhical fancifuul depiction
`
`
`
`
`
`
`
`
`
`
`
`letters ΩΩ (omega) aand Α (alpha). The enntire A is noot included iin the desiggn; rather thhe
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`left angled portion iis truncatedd and joins a depictionn of the Greeek capital lletter Ω. Thhe
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`graphic
`
`
`
`is quite proominent andd exceeds in height thee lettering tto the right
`
`
`
`
`
`
`
`thereof.
`
`
`noted that Itt should be
`
`
`
`Appellant’ss mark utilizzes a depicction of the
`
`
`
`
`
`
`
`
`
`the Greeek letter Ω ((omega), noot the smalll letter formm ώ (omegaa) which is
`
`
`
`
`
`
`
`
`
`
`
`chemicaal/nutritional literature tto denote thhe position
`
`of a carbo
`
`
`
`capital formm of
`
`utilized in t
`
`he
`
`
`
`
`
`
`
`
`
`n in a fatty
`
`
`
`acid, furtheer
`
`
`
`distinguiishing Appeellant’s marrk from beinng indicativve of a posssible ingred
`
`
`
`
`
`
`
`
`
`
`
`ient in the
`
`goods.
`
`
`
`TThe TMEP rrecognizes
`
`
`
`
`
`that compoosite markss may be reegistrable wwhere the
`
`
`
`
`
`
`
`
`
`composite containss two merelly descriptivve terms. AA compositee mark commposed enttirely
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`of the naames of possible ingreedients in thhe goods caan serve ass a trademaark. See
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`T.M.E.PP. § 1209.033(d) (citing In re Colonnial Stores IInc., 394 F.
`
`
`
`
`
`(CCPA 11968) (SUGGAR & SPICCE held noot merely deescriptive off bakery pr
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2d 549, 1557 USPQ 3382
`
`
`
`oducts); In
`
`re
`
`
`
`18
`
`
`
`Shutts, 217 USPQ 363 (TTAB 1983) (SNO-RAKE held not merely descriptive of a snow
`
`removal hand tool).
`
`Particularly in Colonial Stores, the Court of Customs & Patent Appeals
`
`recognized that an unusual association or arrangement in a mark which requires
`
`analysis and rearrangement of the components to suggest the contents of the mark
`
`may function as a trademark. Like the situation in Colonial Stores, where the record
`
`reflected association of SUGAR & SPICE with a nursery rhyme, in the present case
`
`there is evidence of record that OMEGA ALPHA (and design) is evocative of the
`
`converse of a well-known biblical scripture.5
`
`Here, in a situation where neither of the words of the composite mark can
`
`describe or misdescribe any possible ingredients in the mark, the Examining Attorney